2.00 
0.03(1.48%) 1:27PM EDT - Nasdaq Real Time Price
| Prev Close: | 2.03 |
|---|
| Open: | 2.00 |
|---|
| Bid: | 2.00 x 29500 |
|---|
| Ask: | 2.01 x 400 |
|---|
| 1y Target Est: | 3.60 |
|---|
| Beta: | 1.89 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.98 - 2.04 |
|---|
| 52wk Range: | 1.70 - 5.64 |
|---|
| Volume: | 95,738 |
|---|
| Avg Vol (3m): | 322,333 |
|---|
| Market Cap: | 50.66M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.33 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO MeetingPR Newswire(Thu, May 23)
- Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO MeetingCNW Group(Thu, May 23)
- Aeterna Zentaris Announces "At-the-Market" Issuance ProgramCNW Group(Tue, May 21)
- Aeterna Zentaris Announces "At-the-Market" Issuance ProgramPR Newswire(Tue, May 21)
- Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trialsat Motley Fool(Mon, May 20)
- Smaller Companies With Potential For Big Returnsat Seeking Alpha(Thu, May 16)
- Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in TorontoCNW Group(Wed, May 15)
- Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in TorontoPR Newswire(Wed, May 15)
- Tackling Cancer: Endometrial Cancer's Biggest Current & Upcoming Playersat Motley Fool(Sat, May 11)
- Disappointing 1Q Earnings for IARTZacks(Fri, May 10)
- Aeterna Zentaris Announces Election of Directors at its Annual Meeting of ShareholdersCNW Group(Wed, May 8)
- Aeterna Zentaris Announces Election of Directors at its Annual Meeting of ShareholdersPR Newswire(Wed, May 8)
- Æterna Zentaris Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Aeterna Zentaris Reports First Quarter 2013 Financial and Operating ResultsCNW Group(Tue, May 7)
- Aeterna Zentaris Reports First Quarter 2013 Financial and Operating ResultsPR Newswire(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.26 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.74 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan.
View More